Skip to main content

This job has expired

You will need to login before you can apply for a job.

Research Associate II - Gene Therapy Discovery

Employer
Precision BioSciences, Inc.
Location
Durham, NC, United States
Start date
May 23, 2021

View more

Discipline
Science/R&D, Biotherapeutics, Research, Genetics
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Bio NC

Job Details

The Research Associate II will assist in the design and execution of experiments to provide proof-of-concept data for potential therapeutic applications using ARCUS nucleases. As a member of the Gene Therapy Discovery Team, the Research Associate II will support the team in characterizing ARCUS Nucleases across multiple therapeutic targets at the molecular and cellular level.

Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.
  • Work independently and as part of a collaborative team to design, plan, and execute experiments across multiple projects
  • Construct specialized plasmid-based DNA clones for use in all ongoing projects
  • Maintain multiple cell types in culture for the purposes of in vitro testing including primary cells
  • Perform transfection / transduction of ARCUS Nucleases into cultured cells
  • Isolate gDNA, RNA and Protein for downstream assays
  • Analyze in vitro and in vivo experiments at the molecular level (DNA, RNA, or protein) via indel assays, fluorescent analysis by FACS, PCR/digital PCR or ELISA
  • Record laboratory experiments using the electronic notebook system
  • Interpret and analyze experiments that contribute to project goals, presenting data and conclusions at team and project meetings


Qualifications
The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.

Required:
  • BS or MS in Molecular Biology, Biochemistry or related area of study with 2+ years of biopharma industry or academic research experience, or equivalent combination of education and experience
  • Proven track record with basic molecular and biochemical approaches for DNA / RNA / Protein including:
    • RNA/DNA isolation from various tissues/cells
    • Molecular Cloning techniques for Vector construction
    • PCR, digital PCR & DNA Sequencing
    • Mammalian tissue culture (primary cells, cell lines and related aseptic techniques)
    • DNA, RNA Transfection and Viral Transduction for expression in Eukaryotic Cells Systems
    • Protein Characterization by Western, Flow Cytometry, and ELISA
  • Knowledge of DNA sequence analysis software (SnapGene, Vector NTI or similar) and Microsoft Office Suite


Preferred:
  • Experience with genome editing


Travel Requirements
  • This position requires little to no travel.


Location
  • This is an office-based position located at the main headquarters in downtown Durham, NC.


Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. This isnt just a statement supporting the products that were developing its a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs. For additional information, please visit www. precisionbiosciences.com

Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

Company

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Company info
Website
Phone
919-314-5512
Location
302 East Pettigrew Street
Durham
North Carolina
27701
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert